David J. Arthur - May 26, 2022 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Stock symbol
SLRX
Transactions as of
May 26, 2022
Transactions value $
$7,985
Form type
4
Date filed
5/31/2022, 05:17 PM
Previous filing
May 5, 2022
Next filing
Nov 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Purchase $612 +3.4K +1.31% $0.18 263K May 26, 2022 Direct
transaction SLRX Common Stock Purchase $3.39K +18.6K +7.07% $0.18 282K May 26, 2022 Direct
transaction SLRX Common Stock Purchase $127 +708 +0.25% $0.18 282K May 26, 2022 By son F1
transaction SLRX Common Stock Purchase $1.87K +10.4K +3.68% $0.18 293K May 26, 2022 By son F1
transaction SLRX Common Stock Purchase $1.99K +10.8K +3.69% $0.18 304K May 26, 2022 By daughter F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.